罗红霉素治疗小儿呼吸道肺炎支原体感染

COMPARATIVE STUDY ON THE EFFICACY OF ROXITHROMYCIN IN TREATMENT OF CHILDREN′S MYCOPLASMAPNEUMONIAE INFECTION IN RESPIRATORY TRACT

用罗红霉素（２．５～５ｍｇ／ｋｇ，ｂｉｄ）治疗小儿呼吸道肺炎支原体感染４０例，对照组４０例用口服红霉素（１０～１５ｍｇ／ｋｇ，ｔｉｄ）治疗，用药５～１４ｄ。比较两者在治疗小儿呼吸道肺炎支原体感染的疗效及安全性。结果表明，罗红霉素的疗效与红霉素相似，二者的临床有效率（痊愈＋显效）分别为９２．５％和８７．５％，经Ｘ２检验，二者无显著性差异（Ｐ＞０．０５）。罗红霉素组２例出现轻度胃肠道反应，不需中断治疗，且较红霉素组胃肠道副反应发生率低、程度轻。因此，罗红霉素不失为治疗小儿呼吸道肺炎支原体感染的一种安全有效的口服抗生素。

The study were conducted in 80 children with mycoplasmapneumoniae infections in respiratory tract.They are equally divided to receive roxithromycin 2.5～5 mg twice daily for 5～14 days or erythromycin 10～15 mg three times daily for 5～14 days.Results showed that no statistically significant difference was observed in the two groups.However,fewer ADRs are associated with roxithromycin.So it is considered that roxithromycin remain an effective and safe antibiotic for treatment of children′s mycoplasmapneumoniae infections in respiratory tract.